The High Court has declined to step in after Hells Angels’ award of $78,000 in damages for online marketplace Redbubble’s infringement of its trade marks was slashed to just $100, bringing to an end an IP fight that has stretched on for nearly a decade.
Fortescue has brought legal action against start-up Element Zero and three former employees, alleging âindustrial scale misuseâ of the Western Australian mining company’s confidential information.
Drug giant Pfizer has blasted Samsung Bioepis’ âfishing expeditionâ in its suit alleging infringement of the patent for its blockbuster arthritis drug Enbrel, telling the court the Korean biotech should not be allowed to dig for new grounds of invalidity. Â
A judge has upheld Neurim Pharmaceuticalâs claim for additional damages against two generic drug companies found to have infringed its patent for insomnia drug Circadin, despite the company’s failure to comply with an earlier ruling.
Otsuka Pharmaceutical has hit back at suit filed by Indian generics company Sun Pharma seeking to invalidate its patent for blockbuster antipsychotic Abilify, filing a cross-claim seeking to restrain Sun Pharma from infringing the patent with a generic version of the drug.
Drug giant Glaxo has succeeded in extending the term for a patent for a drug that treats chronic obstructive pulmonary disease and asthma, with a delegate rejecting arguments from law firm Banki Haddock Fiora that the application was incorrectly based on a patent that was no longer valid because of amendments.
Seven Network has partially succeeded in appealing a decision that revoked its rights to the ‘7NOW’ trade mark for non-use, with the Full Court finding the broadcaster used the mark on its news promotion website.
A judge has rejected Aristocratâs bid for orders requiring competitor Light & Wonder to hand over documents to be placed âin an envelopeâ for speedy production should its appeal of a decision ordering that it produce the documents to Aristocrat for possible trade secrets suit fail.
South Korean biotech ToolGen has won court approval to patent its genome editing technology CRISPR, after an earlier bid to protect its IP found the revolutionary technology was not patentable.
In a continuing fight over damages stemming from misleading burger ads, McDonald’s has opposed production of sales information to Hungry Jack’s directors and its top executive, saying the information was confidential and the companies “fierce competitors”.